Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).

ABSTRACT:

Aims/introduction

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors improve blood glucose control, as well as reducing bodyweight by promoting urinary glucose excretion. The weight loss is less than expected from urinary glucose loss, however, likely because of an increase in food intake. To investigate whether SGLT-2 inhibitors might increase appetite by affecting related hormones, we examined the effects of the SGLT-2 inhibitor, ipragliflozin, including those on appetite-regulating hormones, in individuals with suboptimally controlled type 2 diabetes.

Materials and methods

The present prospective, multicenter, open-label study was carried out with 96 patients with a body mass index of ≥22 kg/m² who were treated with ipragliflozin (50 mg/day) for 16 weeks. Param

SUBMITTER: Miura H 

PROVIDER: S-EPMC6717805 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature